Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
ImmunityBio Inc stock (US45258J1025): Is its immunotherapy pipeline strong enough to unlock new upside?
ImmunityBio Inc. is positioned as a key player in biotech with its immunotherapy platform designed to combat cancer and infectious diseases. The company’s lead candidate, Anktiva, shows promise in non-muscle invasive bladder cancer, with ongoing trials expanding its potential to other difficult-to-treat cancers. ImmunityBio’s strategy involves combining engineered bacteria, cell therapies, and antibody constructs to stimulate broad immune responses, aiming for long-lasting protection against tumors and addressing large oncology markets.